Lancet study reveals lower rates of stent thrombosis with cobalt-chromium everolimus eluting stents
Published date : 29 April 2012
Article date : 29 April 2012
A network meta-analysis of randomised controlled trials comparing different drug-eluting stents, or drug-eluting with bare-metal stents, has revealed that cobalt-chromium everolimus eluting stents (CoCr-EES) deliver the lowest rate of stent thrombosis within two years of implantation.
The 49 trial sample analysis includes results from more than 50,000 patients and revealed a number of findings. The incidence of 1-year definite stent thrombosis was significantly lower with CoCr-EES than with bare-metal stents (odds ratio [OR] 0·23, 95% CI 0·13—0·41). The significant difference between these stent classes was evident from as early as 30 days, and also in the 31 day - 1 year period. CoCr-EES were also linked to significantly lower rates of 1-year definite stent thrombosis When compared with paclitaxel-eluting stents, permanent polymer-based sirolimus-eluting stents, phosphorylcholine-based zotarolimus-eluting stents, and Resolute zotarolimus-eluting stents.
No other drug-eluting stent had lower definite thrombosis rates compared with bare-metal stents at 2-year follow-up.
The full summary of this study can be found here.
Compare Which Medical Device listings for drug eluting stents here.
